CDK1 and breast carcinoma: It also produces the same effect on MDA-MB-453, androgen-responsive human breast carcinoma cells extensively used in TNBC research, particularly by downregulating the cyclin-dependent kinase 1 (CDK1) and the associated proteins cyclin A and cyclin B [96,97].